Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 1444 results found since Jan 2013.
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages
Int J Mol Sci. 2022 Jul 5;23(13):7461. doi: 10.3390/ijms23137461.ABSTRACTCardiovascular disease (CVD) is causing high mortality worldwide (World Health Organization-WHO, 2015). Atherosclerosis, the hardening and narrowing of arteries caused by the accumulation of fatty acids and lipids (cholesterol plaques), is a main reason of stroke, myocardial infarction, and angina. Present therapies for cardiovascular disease basically use statins such as β-Hydroxy β-methylglutaryl-CoA, with <70% efficacy and multiple side effects. An in vitro investigation was conducted to evaluate the impact of kaempferol, a natural medicat...
Source: Atherosclerosis - July 9, 2022 Category: Cardiology Authors: Etimad Huwait Maha Ayoub Sajjad Karim Source Type: research
Early statin use and cardiovascular outcomes after myocardial infarction: A population-based case-control study
CONCLUSIONS: Lack of statin therapy early after MI is associated with adverse outcomes across the spectrum of MI patients. Results underline the importance of timely statin use after MI.PMID:35803064 | DOI:10.1016/j.atherosclerosis.2022.06.1019
Source: Atherosclerosis - July 8, 2022 Category: Cardiology Authors: Ville Kyt ö Antti Saraste Aleksi Tornio Source Type: research
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrom...
Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research
Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous famili...
Source: Cardiology in Review - June 10, 2022 Category: Cardiology Tags: Review Articles Source Type: research
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Prog Cardiovasc Dis. 2022 May 19:S0033-0620(22)00046-9. doi: 10.1016/j.pcad.2022.05.003. Online ahead of print.ABSTRACTInternational guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with stati...
Source: Atherosclerosis - May 23, 2022 Category: Cardiology Authors: Kosmas I Paraskevas Peter Gloviczki Pier Luigi Antignani Anthony J Comerota Alan Dardik Alun H Davies Hans-Henning Eckstein Gianluca Faggioli Jose Fernandes E Fernandes Gustav Fraedrich George Geroulakos Jonathan Golledge Ajay Gupta Victor S Gurevich Arka Source Type: research
Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
Conclusions and RelevanceThis study identified the price at which inclisiran is cost effective for the US health system, at generally accepted willingness-to-pay thresholds.
Source: American Journal of Cardiovascular Drugs - May 21, 2022 Category: Cardiology Source Type: research
